Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 16, 2026Investment Snapshot
- Trading 3% below Graham Number — thin margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 39.4% with 104.3% net margin
- Revenue growing at 67% annually
Theravance Biopharma, Inc. - Ordinary Shares (TBPH) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $836 million . Key value metrics: P/E ratio 7.3, P/B ratio 2.88, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Theravance Biopharma, Inc. - Ordinary Shares — Fundamental Analysis Summary
Theravance Biopharma, Inc. - Ordinary Shares (TBPH) is trading 3% below its Graham Number of $16.79, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 7.3x.
On financial health, TBPH shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 39.4% (sector average: -20.6%).
StockPik's composite Value Score for TBPH is 97/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TBPH shows revenue growing at 67% year-over-year, with earnings growing at 288%.